 |
 Video: What is a Stock Split?
|
|
|
| BioMarin Pharmaceutical is a global biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products include: Vimizim (elosulfase alpha); Naglazyme (galsulfase); Kuvan (sapropterin dihydrochloride); Palynziq (pegvaliase-pqpz); Brineura (cerliponase alfa); Voxzogo (vosoritide); and Aldurazyme (laronidase). Co.'s clinical development programs include: Valoctocogene roxaparvovec, which is an adeno associated virus (AAV5) vector drug development candidate; BMN 307, which is an AAV5 mediated gene therapy; and BMN 225, which is a small-molecule therapy. According to our BMRN split history records, BioMarin Pharmaceutical has had 0 splits. | |
|
BioMarin Pharmaceutical (BMRN) has 0 splits in our BMRN split history database.
Looking at the BMRN split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into BioMarin Pharmaceutical shares, starting with a $10,000 purchase of BMRN, presented on a split-history-adjusted basis factoring in the complete BMRN split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
04/22/2014 |
|
| End date: |
04/17/2024 |
|
| Start price/share: |
$61.99 |
|
| End price/share: |
$90.47 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
45.94% |
|
| Average Annual Total Return: |
3.85% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$14,587.31 |
|
| Years: |
9.99 |
|
|
|
|
|
